Joenja is indicated for the treatment of activated phosphoinositide 3-kinase delta (P13Kd) syndrome (APDS) in adult and paediatric patients 12 years of age and older.

Testing prior to treatment with Joenja Pregnancy status in females of reproductive potential should be verified prior to initiating treatment with Joenja (see sections 4.4 and 4.6). Posology The recommended dosage of Joenja in adult and paediatric patients 12 years of age and older weighing 45 kg or greater is 70 mg administered orally twice daily approximately 12 hours apart, with or without food. There is no recommended dosage for patients weighing less than 45 kg. Missed dose If a dose is missed by more than 6 hours, patients should wait and take the next dose at the usual time. If vomiting occurs within 1 hour after taking Joenja, patients should take Joenja as soon as possible. If vomiting occurs more than 1 hour after dosing, patients should wait and take the next dose at the usual time.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Embryo-foetal toxicity Based on findings in animals, Joenja may cause foetal harm when administered to a pregnant woman. Administration of leniolisib to rats and rabbits during the period of organogenesis caused embryo-foetal toxicity including malformations at exposures that were 2 to 6 times higher than the maximum recommended human dose (MRHD) in APDS patients based on AUC comparisons. The pregnancy status of patients of reproductive potential should be verified prior to starting treatment. Pregnant women should be advised of the potential risk to a foetus. Females of reproductive potential should be advised to use highly effective methods of contraception during treatment and for 1 week after the last dose. Vaccinations Live, attenuated vaccinations may be less effective if administered during Joenja treatment. Excipients with known effect Lactose content This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption must not take this medicine. Sodium content This medicinal product contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially ‘sodium-free’.

Effect of other drugs on Joenja Strong and moderate CYP3A4 inhibitors Joenja is a substrate of CYP3A4. Leniolisib exposure was increased 2-fold when co-administered with itraconazole, a strong CYP3A4 inhibitor. Physiological based pharmacokinetic (PBPK) model-based simulations predicted a maximum increase of 75% in leniolisib AUC0-12 with erythromycin (moderate CYP3A4 inhibitor). Concomitant use of Joenja with strong and moderate CYP3A4 inhibitors (e.g., clarithromycin, cobicistat, danoprevir, dasabuvir, diltiazem, elvitegravir, erythromycin, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir, ombitasvir, paritaprevir, posaconazole, ritonavir, saquinavir, telithromycin, tipranavir, troleandomycin, verapamil, voriconazole) should be avoided. Strong and moderate CYP3A4 inducers Concomitant use of strong and moderate CYP3A4 inducers may result in reduced leniolisib exposure and thus reduced leniolisib efficacy. PBPK model-based simulations predicted a maximum decrease of 78% and 58% in leniolisib AUC0-12 with rifampin (strong CYP3A4 inducer) and efavirenz (moderate CYP3A4 inducer), respectively. Therefore, concomitant use of Joenja with strong and moderate CYP3A4 inducers (e.g., avasimibe, carbamazepine, mitotane, phenobarbital, phenytoin, rifabutin, rifampin, St. John’s Wort, bosentan, efavirenz, etravirine, modafinil, nafcillin, nevirapine) should be avoided. CYP2D6 and P-gp inhibitors Quinidine (strong P-gp and CYP2D6 inhibitor) had no effect on leniolisib systemic exposure. Leniolisib is not a sensitive substrate of P-gp and CYP2D6. Effect of Joenja on other drugs CYP1A2 metabolized drugs with a narrow therapeutic index Leniolisib inhibits CYP1A2 in a time-dependent manner in vitro. Concomitant use of Joenja with drugs that are primarily metabolized by isoenzyme CYP1A2 and have a narrow therapeutic index (e.g., alosetron, caffeine, duloxetine, melatonin, ramelteon, tasimelteon, theophylline, tizanidine) should be avoided. BCRP, OATP1B1, and OATP1B3 substrates In vitro, leniolisib is a substrate and an inhibitor of the hepatic efflux transporter BCRP and a substrate of P-gp. Leniolisib was identified in vitro as a potential inhibitor of the hepatic uptake and efflux transporters OATP1B1/B3 and BCRP. The effect of Joenja on BCRP, OATP1B1, and OATP1B3 substrates has not been studied clinically. Due to a possible increase in systemic exposure of these substrates, concomitant use of Joenja with drugs that are BCRP, OATP1B1, and OATP1B3 substrates (e.g., rosuvastatin, pitavastatin, letermovir) should be avoided. Oral contraceptives When combined with a monophasic oral contraceptive containing levonorgestrel and ethinylestradiol, leniolisib increased ethinylestradiol exposure by approximately 25 to 30% in terms of both AUC and Cmax, but did not affect the Cmax or AUC of levonorgestrel. Efficacy of a combined oral contraceptive composed of ethinylestradiol and levonorgestrel is not expected to be compromised by concomitant use with leniolisib. Gastric acid reducing agents Leniolisib exhibits pH-dependent solubility (pH range of 1.2 to 4), with low solubility at higher pH values (= 5). However, PK results from APDS patients did not indicate that acid reducing agents (e.g., H2-antagonists, proton pump inhibitors) have a clinically relevant effect on leniolisib systemic exposure. Paediatric population

Women of childbearing potential/contraception in females Women of childbearing potential should use highly effective methods of contraception during treatment with Joenja and for 1 week after the last dose. Leniolisib can cause foetal harm based on findings from animal studies. Pregnancy status in females of reproductive potential should be verified prior to initiating treatment with Joenja. Pregnancy There are no data from the use of leniolisib in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Joenja is not recommended during pregnancy and in women of childbearing potential not using highly effective methods of contraception. Breast-feeding There are no data on the presence of leniolisib or its metabolites in human milk or the effects on the breastfed infant or milk production. Available pharmacokinetic/toxicological data in animals have shown excretion of leniolisib in milk (see section 5.3). Because of the potential for serious adverse reactions from leniolisib in the breastfed child, women should be advised not to breastfeed during treatment with Joenja and for 1 week after the last dose.

Leniolisib has no or negligible influence on the ability to drive and use machines.

The safety of Joenja reflects exposure based on 38 adult and paediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS) from the placebo-controlled portion of Study 2201 and additional open-label clinical safety data. Thirty-seven of 38 patients received Joenja 70 mg orally twice daily for at least 60 weeks and 81% were exposed for 96 weeks or longer. Median duration of Joenja treatment was approximately 3 years, and 5 patients had more than 5 years of Joenja exposure. The data below are based on the 12-week, placebo-controlled portion of Study 2201 in which either Joenja 70 mg (N=21) or placebo (N=10) was administered twice daily to patients with APDS. Demographics of the patients who participated in this study are summarized in section 5.1. Table 1 presents adverse reactions that occurred in 2 or more patients treated with Joenja and for which the incidence in patients treated with Joenja was greater than the incidence in patients treated with placebo. The most common adverse reactions (> 10%) were headache, sinusitis, and atopic dermatitis. Adverse reactions are listed in Table 1 by system organ class and frequency. Frequencies are defined as: very common (= 1/10), common (= 1/100 to < 1/10), uncommon (= 1/1 000 to < 1/100), and rare (= 1/10 000 to < 1/1 000), and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. Table 1 Adverse reactions reported by 2 or more Joenja-treated patients and more frequently than placebo System organ class Adverse reactions Frequency Infections and infestations Sinusitis Very common Nervous system disorders Headache Very common Cardiac disorders Tachycardia1 Very common Gastrointestinal disorders and administration site conditions Diarrhoea Very common Skin and subcutaneous tissue disorders Dermatitis atopic2 Alopecia Very common Very common Musculoskeletal and connective tissue disorders Back pain Neck pain Very common Very common General disorders and administration site conditions Fatigue Pyrexia Very common Very common 1Tachycardia: including tachycardia and sinus tachycardia 2Dermatitis atopic: including dermatitis atopic and eczema Description of selected adverse reactions Laboratory abnormalities Seven (33%) patients receiving Joenja developed an absolute neutrophil count (ANC) between 500 and 1500 cells/microL (0.5-1.5 x 109/L). No patients developed an ANC < 500 cells/microL (0.5-1.5 x 109/L) and there were no reports of infection associated with neutropenia. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

If occurs, the patient should be monitored for any signs or symptoms of adverse reactions. Treatment of with Joenja consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient.

Pharmacotherapeutic group: Immunostimulants, other immunostimulants, ATC code: L03AX22 Mechanism of action Leniolisib inhibits PI3K-delta by blocking the active binding site of PI3K-delta. In cell-free isolated enzyme assays, leniolisib was selective for PI3K-delta over PI3K-alpha (28-fold), PI3K-beta (43-fold), and PI3K-gamma (257-fold), as well as the broader kinome. In cell-based assays, leniolisib reduced pAkt pathway activity and inhibited proliferation and activation of B and T cell subsets. Gain-of-function variants in the gene encoding the p110-delta catalytic subunit or loss of function variants in the gene encoding the p85-alpha regulatory subunit each cause hyperactivity of PI3K-delta. Leniolisib inhibits the signalling pathways that lead to increased production of PIP3, hyperactivity of the downstream mTOR/Akt pathway, and to the dysregulation of B and T cells. Pharmacodynamic effects Ex vivo pharmacodynamics of leniolisib [proportion of phosphorylated Akt (pAkt)- positive B cells] were assessed intra-individually at 10, 30, and 70 mg twice daily for 4 weeks at each dose level in patients with APDS. Within the explored dose range, higher leniolisib plasma concentrations were generally associated with higher reduction of pAkt-positive B cells and higher doses were associated with a slightly higher peak reduction as well as more sustained reduction. Treatment with Joenja 70 mg twice a day at steady state is estimated to produce time-averaged reduction of pAkt-positive B cells by approximately 80%. Clinical efficacy and safety The efficacy of Joenja was evaluated in the placebo-controlled portion of Study 2201, a 12-week blinded, randomized, placebo-controlled study in adult and paediatric patients 12 years of age and older with confirmed APDS-associated genetic PI3Kd mutation with a documented variant in either PIK3CD or PIK3R1. Baseline patient demographics are shown in Table 2. Table 2 Baseline demographic and disease characteristics in patients with APDS (Study 2201) Demographics and disease characteristics Joenja (N=21) Placebo (N=10) Demographics Age1 (Years) Mean (SD) 22.2 (10.00) 26.7 (13.43) Age categories < 18, n (%) (Min, Max) = 18, n (%) (Min, Max) 8 (38) (12, 17) 13 (62) (18, 54) 4 (40) (15, 17) 6 (60) (18, 48) Sex, n (%) Male Female 11 (52) 10 (48) 4 (40) 6 (60) Race, n (%) Asian Black White Other 1 (5) 1 (5) 18 (86) 1 (5) 1 (10) 1 (10) 7 (70) 1 (10) Ethnicity, n (%) Hispanic or Latino Not Hispanic or Latino Not reported 0 14 (67) 7 (33) 1 (10) 7 (70) 2 (20) Disease characteristics APDS 1 (PIK3CD variant), n (%) 16 (76) 9 (90) APDS 2 (PIK3R1 variant), n (%) 5 (24) 1 (10) Concomitant glucocorticoids, n (%) 12 (57) 6 (60) Concomitant immunoglobulin G (IgG), n (%) 14 (67) 7 (70) Previous rapamycin/sirolimus use, n (%) 4 (19) 3 (30) 1Patient age from study Day -4 up to initial Joenja dosing Patients had nodal and/or extranodal lymphoproliferation, as measured by index nodal lesion selected by the Cheson methodology on CT or MRI and clinical findings and manifestations compatible with APDS (e.g., history of repeated oto-sino-pulmonary infections, organ dysfunction). Immunosuppressive medications or PI3Kd inhibitors (selective or non-selective) were prohibited within 6 weeks of baseline (Day -1 and the visit prior to first study drug administration) and throughout the study. In addition, patients who had previous or concurrent B cell depleters (e.g., rituximab) within 6 months of baseline were excluded from the study, unless absolute B lymphocytes in the blood were normal. B cell depleters were prohibited throughout the study. Thirty-one patients were randomized 2:1 to receive either Joenja 70 mg (N=21) or placebo (N=10) twice a day for 12 weeks. The co-primary efficacy endpoints were improvement in lymphoproliferation as measured by a change from baseline in lymphadenopathy measured by the log10-transformed sum of product diameters and the normalization of immunophenotype as measured by the percentage of naïve B cells out of total B cells. Both co-primary efficacy endpoints were statistically significant (Table 3). Table 3 Co-primary endpoints in placebo-controlled portion of Study 2201 at Week 12 (Day 85) Joenja Placebo (N=21) (N=10) Log10-transformed SPD of index lesions (excluding patients with 0 lesions at Baseline)a nb 18 8 Baseline Mean (SD) 3.03 (0.42) 3.05 (0.39) Change from Baseline, LS Mean (SE) -0.27 (0.04) -0.02 (0.05) Difference vs. Placebo (95% CI) -0.25 (-0.38, -0.12) p-value 0.0006 Percentage of naïve B cells out of total B cells (patients with < 48% of naïve B cells at Baseline)c nd 8 5 Baselinee Mean (SD) 27.16 (13.16) 30.51 (7.97) Change from Baseline, LS Mean (SE) 37.39 (5.34) 0.09 (6.66) Difference vs. Placebo (95% CI) 37.30 (24.06, 50.54) p-value 0.0002 CI=confidence interval; SD= Standard deviation; SE=standard error; SPD=sum of product diameters; vs=versus; LS Mean: Least-squares mean Note: The LS mean change from baseline, difference in LS mean change from baseline between Joenja and placebo and its p-value were obtained from an Analysis of Covariance model with treatment, glucocorticoids use and immunoglobulin replacement therapy at baseline, and baseline measurement as covariates. aChange in index lesion size was measured using the log10 transformed sum of the product of diameters (SPD) of the largest lymph nodes (maximum of 6) identified as per the Cheson criteria on CT/MRI. bThe analysis excluded 2 patients from each treatment group due to protocol deviations and 1 Joenja patient having complete resolution of the index lesion identified at baseline. cCell surface markers used to distinguish naïve B cells on flow cytometry were CD19+CD27- CD10-. dThe analysis excluded 2 patients from each treatment group due to protocol deviations, 5 Joenja patients and 3 placebo patients with more than or equal to 48% naïve B cells at baseline, 5 Joenja patients with no Day 85 measurement, and 1 Joenja patient with no baseline measurement. eBaseline is defined as the arithmetic mean of the Baseline and Day 1 values when both were available, and if either value was missing, the existing value was used. Figure 1 represents the co-primary endpoints grouped by age (< 18 years of age vs = 18 years of age). Figure 1 Difference from baseline in log10 transformed SPD of index lesions and percentage of naïve B cells out of total B cells (patients with < 48% of naïve B cells at Baseline) by age group Paediatric population For adolescents aged 12 to 17 years, please see above. The Medicines and Healthcare products Regulatory Agency has deferred the obligation to submit the results of studies with leniolisib in one or more subsets of the paediatric population in APDS (see section 4.2 for information on paediatric use).

The systemic drug exposure (AUC and Cmax) of leniolisib increased dose proportionally within the studied range of doses (20 to 140 mg twice a day dosing and single doses of 10 to 400 mg). During twice daily dosing approximately 12 hours apart, leniolisib accumulates approximately 1.4-fold (range of 1.0 to 2.2) in achieving steady-state, consistent with an effective half-life (t1/2) of approximately 7 hours. Steady state drug concentrations can be expected to be reached after approximately 2 to 3 days of Joenja treatment. The pharmacokinetics of leniolisib are similar between healthy participants and APDS patients. Absorption In a placebo controlled, single and multiple ascending dose study in healthy participants, leniolisib median time to maximum plasma concentration (Tmax) occurred at about 1 hour postdose. Tmax appeared independent of dose and was not altered after multiple oral doses. Food is unlikely to have a clinically meaningful effect on the systemic exposure of leniolisib during Joenja treatment (see section 4.2). Distribution The systemic decay in leniolisib plasma concentration over time is bi-exponential, indicating a distribution delay towards peripheral tissues. The apparent terminal elimination t1/2 is approximately 10 hours. The volume of distribution of leniolisib is estimated to be 28.5 L in patients with APDS. Leniolisib was highly bound (94.5%) to plasma proteins. Biotransformation Leniolisib was 60% metabolized by the liver, with CYP3A4 being the most predominant enzyme involved (95.4%) in the primary oxidative metabolism of leniolisib with minor contribution from other enzymes (3.5% CYP3A5, 0.7% CYP1A2 and 0.4% CYP2D6). Intestinal secretion by BCRP as well as extrahepatic CYP1A1 cannot be excluded as excretion routes. Elimination The mean recovery of total 14C-radioactivity following a single oral dose of 70 mg 14C-leniolisib was 92.5% (67.0% and 25.5% recovered via faeces and urine, respectively) 168 hours postdose. Unchanged leniolisib (6.32%) was the predominant drug-related material recovered in urine. Paediatric patients Following a single 70 mg oral dose of leniolisib in APDS patients, leniolisib systemic exposures were comparable between paediatric patients (12 to 17 years of age) and adults (= 18 years of age), with median Tmax (ranging from 1 to 5 hours) reached approximately 3 hours post-dose in patients 12 to 17 years of age. The observed difference in the median Tmax between paediatric patients (12 to 17 years of age) and adults (= 18 years of age) is not clinically relevant given the PK variability and comparable concentration-time profiles between the two age groups. Hepatic impairment The effect of hepatic impairment on the pharmacokinetics of leniolisib has not been evaluated. As leniolisib is metabolized to a large extent by the liver (60%), use of Joenja is not recommended in patients with moderate to severe hepatic impairment.

Genotoxicity and carcinogenicity Carcinogenicity studies have not been conducted with leniolisib. Leniolisib was not genotoxic in the in vitro Ames assay, in vitro chromosomal aberration assay in human lymphocytes, or micronucleus assays in TK6 cells (in vitro) and rats (in vivo). Reproductive and developmental toxicity In a fertility study, male rats had decreased round spermatids and decreased spermatocytes in the testis at an oral dose of 90 mg/kg/day (approximately 2 times the MRHD on an AUC basis). Leniolisib had no effect on fertility in female rats at oral doses up to 90 mg/kg/day (approximately 4 times the MRHD on an AUC basis). No effects on male or female fertility and reproductive performance indices were observed up to the maximum dose administered of 90 mg/kg/day (approximately 2 to 4 times the MRHD on an AUC basis). Leniolisib was administered orally to pregnant rats at doses of 10, 30, and 120 mg/kg/day during the period of organogenesis from gestation Day 6 to Day 17. Leniolisib at a dose of 120 mg/kg/day was associated with decreased foetal body weight, visceral and skeletal variations, and external, visceral, and skeletal malformations (eye bulge, microphthalmia, anophthalmia, and reduction in orbital socket size) in the presence of maternal toxicity (decrease in body weight gain) at exposures approximately 6 times the MRHD on an AUC basis. No developmental toxicity was observed in rats at an exposure approximately 2 times the MRHD (on an AUC basis at a maternal oral dose of 30 mg/kg/day). Leniolisib was administered orally to pregnant rabbits at doses of 10, 30, and 100 mg/kg/day during the period of organogenesis from gestation Day 7 to Day 20. Leniolisib at a dose of 100 mg/kg/day was associated with skeletal variations as well as visceral and skeletal malformations (microphthalmia and reduction in orbital socket size) in the presence of maternal toxicity (decrease in body weight gain) at exposures approximately 2 times the MRHD on an AUC basis. No developmental toxicity was observed in rabbits at an exposure approximately 0.3 times the MRHD (on an AUC basis at a maternal oral dose of 30 mg/kg/day). In the pre- and postnatal developmental rat toxicity study, adverse effects on the progeny during the preweaning period, manifested as reduced pup survival and persistently lower pup weight during postweaning, were seen at maternal doses of 90 mg/kg/day. Leniolisib was detected in all lactation study samples, with leniolisib concentrations increasing in a dose-dependent manner resulting in a concentration that was approximately 2 to 3-fold higher than the maternal plasma concentration at 10 to 30 mg/kg/day. Juvenile animal toxicity data Studies were conducted with leniolisib in juvenile rats starting at postnatal day (PND) 7 (the equivalent of a human newborn) to PND 77 (the equivalent of a human adult). Death was observed in juvenile rats that received 90 mg/kg/day, approximately 9 times the MRHD on an AUC basis (measured after the first dose) and occurred primarily during the pre-weaning period (PND 9 to PND 15). Changes in the onset of puberty (delays in males and accelerations in females) were observed in juvenile rats at equal to or greater than 30 mg/kg/day leniolisib, which is one half to equivalent to, the MRHD on an AUC basis. A no effect dose level was identified at an exposure approximately 0.1 to 1.0 times the MRHD on an AUC basis.

Tablet core Lactose monohydrate Microcrystalline cellulose Hypromellose Sodium starch glycolate Magnesium stearate Colloidal anhydrous silica Tablet film-coating Hypromellose Titanium dioxide Iron oxide monohydrate yellow Iron oxide red Talc Polyethylene glycol

Not applicable.

48 months

Do not store above 25°C. Do not refrigerate.

High density polyethylene bottles with aluminium induction seal and child resistant polypropylene screw cap. Each pack contains 1 bottle with 60 tablets.

No special requirements. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Feb. 16, 2026

spc-doc_PLGB 33010-0001.pdf

Bulk SPC upload Feb2026